A high-purity ARA 290 peptide store provides laboratory researchers with access to analytical-grade Cibinetide (ARA 290), an erythropoietin-derived peptide engineered to selectively target the innate repair receptor (IRR). Sourcing from verified USA suppliers ensures lot-specific HPLC/MS validation, low endotoxin levels, and consistent batch purity for preclinical in vitro and animal models.
A high-purity ARA 290 peptide store provides laboratory researchers with access to analytical-grade Cibinetide (ARA 290), an erythropoietin-derived peptide engineered to selectively target the innate repair receptor (IRR). Sourcing from verified USA suppliers ensures lot-specific HPLC/MS validation, low endotoxin levels, and consistent batch purity for preclinical in vitro and animal models.
ARA 290, also known as Cibinetide or pyroglutamate helix B surface peptide (pHBSP), is an 11-amino acid peptide derived from the spatial structure of erythropoietin (EPO). Unlike native EPO, which primarily stimulates erythropoiesis by binding to the homodimeric erythropoietin receptor (EPOR2), ARA 290 is engineered to selectively target the innate repair receptor (IRR). The IRR is a heteromeric complex composed of two erythropoietin receptor subunits and two common beta receptor (CD131) subunits.
When sourcing materials from an ARA 290 peptide store, researchers are typically investigating cellular response pathways activated during tissue injury, localized ischemia, or severe inflammation. Because ARA 290 lacks affinity for the homodimeric EPOR complex, preclinical studies demonstrate that it does not stimulate red blood cell production, reticulocytosis, or changes in hematocrit. This functional separation allows investigators to isolate tissue-protective and anti-inflammatory signaling cascades without confounding hematological variables.
In laboratory settings, ARA 290 serves as a pivotal tool for dissecting the downstream signals of CD131-mediated repair. By exploring our broader catalog of research peptides, laboratories can cross-reference ARA 290 with other targeted signaling molecules to build comprehensive experimental models.
The primary mechanism of ARA 290 relies on its high-affinity interaction with the innate repair receptor (IRR). Under homeostatic conditions, IRR expression on parenchymal, vascular, and immune cells is minimal. However, upon exposure to cellular stress, tissue hypoxia, or pro-inflammatory cytokines such as TNF-alpha and IL-1beta, IRR expression is rapidly upregulated.
Binding of ARA 290 to the IRR initiates an intracellular signaling cascade that inhibits pro-inflammatory pathways, specifically suppressing nuclear factor kappa B (NF-kB) activation and downstream transcription of inflammatory mediators. Preclinical in vitro assays reveal that this engagement stabilizes mitochondrial membrane potential, reduces reactive oxygen species (ROS) accumulation, and prevents stress-induced apoptosis in endothelial and neural cell lines.
Researchers analyzing these pathways can consult the PX1 research library to evaluate technical documentation on receptor cross-talk and signal transduction dynamics associated with erythropoietin-derived ligands.
A substantial body of literature documents the application of ARA 290 across diverse animal and cellular models of tissue injury. In rodent models of peripheral neuropathy and small fiber nerve pathology, investigators have noted that ARA 290 administration correlates with decreased neuroinflammatory activity and enhanced axonal survival. In vitro assays using cultured primary Schwann cells further indicate that ARA 290 attenuates cytokine release following metabolic insult.
In ischemic and reperfusion models—such as renal, myocardial, and focal cerebral ischemia—preclinical data suggest that ARA 290 decreases local neutrophil infiltration and preserves vascular endothelial integrity. Because the peptide acts directly on the IRR rather than systemic blood pressure or oxygen-carrying capacity, it provides a clean baseline for evaluating isolated tissue protection.
Furthermore, rodent models of metabolic dysfunction and chronic inflammatory stress show marked reductions in inflammatory cell recruitment within adipose and vascular tissues following ARA 290 exposure, underscoring its utility in multi-system inflammatory models.
When designing preclinical experiments focused on tissue protection and inflammatory modulation, researchers frequently compare ARA 290 against other cytoprotective peptides within similar experimental frameworks. While ARA 290 acts specifically through the heterodimeric innate repair receptor (EPOR/CD131), alternative research peptides operate via distinct, non-overlapping pathways.
For instance, BPC-157 is frequently evaluated in models of musculoskeletal and gastrointestinal repair due to its influence on VEGFR2 expression and focal adhesion kinase pathways. Conversely, KPV, a tripeptide fragment of alpha-MSH, operates primarily through PepT1 internalization to inhibit NF-kB in epithelial cells. In anti-microbial and immunomodulatory studies, researchers often utilize LL-37 to measure host-defense responses and chemokine recruitment. Comparing ARA 290 to these compounds provides researchers with a multi-faceted approach to studying inflammatory signaling cascades in vitro.
The following table summarizes key biological targets and experimental domains for these distinct research compounds:
Selecting a qualified ARA 290 peptide store requires evaluating strict analytical verification practices. Because small peptide impurities or residual solvents can invalidate cell culture assays or animal studies, researchers must mandate lot-specific documentation prior to procurement.
High-Performance Liquid Chromatography (HPLC) is the standard method for establishing chemical purity. A reliable supplier provides an HPLC chromatogram showing a primary peak area exceeding 98.0%, confirming the absence of truncated sequences or synthesis side-products. Mass Spectrometry (MS) must accompany HPLC data to verify the exact molecular mass of the 11-amino acid peptide, confirming molecular identity against target parameters.
Equal critical focus must be placed on endotoxin content. For cell-based assays and rodent research, bacterial endotoxins (lipopolysaccharides) induce non-specific immune activation, confounding experimental outcomes. A reputable vendor conducts Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels remain strictly below industrial thresholds (typically <0.01 EU/mg).
PX1 Research maintains rigorous quality assurance protocols by ensuring all peptide synthesis occurs in modern, GMP-compliant facilities located within the USA. Domestic manufacturing eliminates international supply chain vulnerabilities while guaranteeing adherence to stringent environmental and process controls.
Every batch of ARA 290 undergoes independent verification at an ISO 17025-accredited laboratory. This third-party oversight confirms that purity, identity, and sequence integrity meet rigid scientific specifications. Certificates of Analysis (COAs) are generated for every individual lot and made readily accessible to researchers upon request.
By enforcing batch-to-batch consistency and full traceability, PX1 Research empowers academic institutions, biotechnology firms, and independent laboratories to conduct reproducible, high-impact research. Investigators interested in bulk procurement or customized analytical reporting can establish institutional accounts through our wholesale program.
To preserve the structural integrity of ARA 290 during in vitro or animal experimentation, proper laboratory handling and reconstitution procedures must be followed. The peptide is supplied as a lyophilized (freeze-dried) powder to maximize shelf stability.
Reconstitution should be performed using sterile, laboratory-grade diluents such as Bacteriostatic Water, Sterile Saline (0.9% NaCl), or phosphate-buffered saline (PBS), depending on the specific assay requirements. For detailed step-by-step instructions on calculating concentrations and selecting diluents, researchers can review our dedicated peptide reconstitution guide.
During reconstitution, diluent should be introduced gently along the glass wall of the vial. Swirl the vial with light rotational movements; avoid vigorous shaking or vortexing, as mechanical shear stress can disrupt secondary peptide structures or induce aggregation. All preparation steps must occur within a laminar flow hood using aseptic technique.
Lyophilized ARA 290 should be stored in a dry, dark environment at -20°C for short-to-medium-term stability, or at -80°C for long-term preservation. Under these conditions, the peptide maintains analytical purity and biological activity for extended periods.
Once reconstituted into aqueous solution, ARA 290 exhibits reduced stability. Reconstituted aliquots should be stored at 2°C to 8°C for short-term use (typically up to 7–14 days depending on the buffer) or flash-frozen in single-use working volumes at -80°C to avoid repeated freeze-thaw cycles. Repeated thawing degrades peptide chains and reduces experimental reproducibility.
When designing in vitro experiments, researchers should account for the biological half-life of ARA 290 in cell culture media. Addition of protease inhibitors or media optimization may be necessary depending on the enzymatic activity of the specific cell line under investigation.
Acquiring high-purity peptides for ongoing research protocols requires a dependable supply partner capable of supporting both small-scale screening and large-scale preclinical trials. PX1 Research operates centralized distribution hubs in California and Arizona to streamline logistics across North America.
Orders placed Monday through Friday before cut-off times qualify for same-day dispatch, minimizing transit delays and ensuring temperature-controlled packaging maintains product integrity. Institutional buyers benefit from transparent documentation, lot tracking, and dedicated technical support.
Whether sourcing single vials for preliminary assays or securing bulk quantities through our wholesale portal, PX1 Research delivers analytical consistency backed by USA-based manufacturing and ISO 17025 quality verification.
What is ARA 290 and how is it used in laboratory research?
ARA 290 (Cibinetide) is an 11-amino acid peptide derived from erythropoietin. In laboratory research, it is used exclusively to study the innate repair receptor (IRR) signaling pathway, inflammatory modulation, and tissue protection in vitro and in animal models.
Does ARA 290 stimulate red blood cell production in preclinical models?
No. Preclinical literature demonstrates that ARA 290 selectively binds the heterodimeric innate repair receptor (EPOR/CD131) without activating the homodimeric erythropoietin receptor responsible for erythropoiesis.
How does PX1 Research verify the purity of ARA 290?
PX1 Research verifies every lot of ARA 290 using High-Performance Liquid Chromatography (HPLC) for purity, Mass Spectrometry (MS) for identity confirmation, and LAL assays for endotoxin quantification at an independent ISO 17025-accredited lab.
What are the recommended storage conditions for ARA 290?
Lyophilized ARA 290 should be stored at -20°C or -80°C away from light. Reconstituted solutions should be aliquoted and stored at -80°C to prevent degradation from repeated freeze-thaw cycles.
Which diluent is appropriate for reconstituting ARA 290 for laboratory assays?
Common laboratory diluents include sterile bacteriostatic water, 0.9% sterile saline, or phosphate-buffered saline (PBS), selected based on the requirements of the specific cell culture or animal model.
What is the typical endotoxin limit for research-grade ARA 290?
PX1 Research ensures that endotoxin levels in research-grade ARA 290 remain strictly below 0.01 EU/mg, preventing non-specific immune reactions in cellular or in vivo assays.
Where is PX1 Research ARA 290 manufactured and shipped from?
All PX1 Research peptides are manufactured in GMP-compliant facilities in the USA and shipped directly from distribution hubs located in California and Arizona.
Can institutions purchase ARA 290 in bulk for large-scale studies?
Yes. Institutional accounts, academic laboratories, and corporate researchers can access bulk pricing and custom lot documentation through the PX1 Research wholesale program.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.